האיגוד הישראלי לרפואת משפחה
כעת 6832 ערכים
רופאים, הרשמו עכשיו למועדון העורכים כניסה עקבו אחרינו בפייסבוק
האיגוד הישראלי לרפואת משפחה
רופאים, הרשמו עכשיו למועדון העורכים כניסה עקבו אחרינו בפייסבוק
כעת 6832 ערכים
האיגוד הישראלי לרפואת משפחה

המלצות כוח המשימה הישראלי בנושא קידום בריאות ורפואה מונעת/ביבליוגרפיה מהדורת 2000

מתוך ויקירפואה

Preventative (1).png

המלצות כוח המשימה הישראלי בנושא קידום בריאות ורפואה מונעת
מאת איגוד רופאי המשפחה בישראל, האגף למדיניות רפואית, ההסתדרות הרפואית בישראל

הפרק הבא הפרק הקודם

תוכן עניינים > פרק #25: המלצות כוח המשימה הישראלי בנושא קידום בריאות ורפואה מונעת/ביבליוגרפיה מהדורת 2000

המלצות כוח המשימה הישראלי בנושא
קידום בריאות ורפואה מונעת
Ambox warning blue.png
ערך זה הוא הנחיה קלינית סגורה לעריכה
המלצות כוח המשימה.png
שם הפרק ביבליוגרפיה מהדורת 2000
עורך מדעי פרופסור אמנון להד, פרופ' חוה טבנקין, ד"ר תם אקסלרוד
מוציא לאור ההסתדרות הרפואית בישראל, האגף למדיניות רפואית, איגוד רופאי המשפחה בישראל
מועד הוצאה אוקטובר 2022
מספר עמודים 284
קישור באתר ההסתדרות הרפואית
Logo small.gif


  1. United States Preventive Services Task Force. Guide to clinical Preventive Service. Second Edition. Baltimore Md: Williams & Wilkins 1996. Update: www.preventiveservices.ahrq.gov
  2. Canadian Task Force on the Periodic Health Examination. The Canadian Guide to Clinical Preventive Health care. Canada Communication group publishing 1998.
  3. Sox HC. Preventive Health Services in Adults. N Engl J Med 1994; 330: 1589-1595.
  4. Battista RN, Lawrence RS eds. Implementing preventive Services. Am J Prev Med 1988; 4 (supp 8).
  5. Bravrman P.A & Tarimo A. Screening in Primary health care-Setting priorites with limited resources. WHO Publication 1994.
  6. Prevention in Primary Care- Recommendations for promoting good-practice-CINDI 2000 Editied by Dobrossy, WHO Regional office for Europe Publication, 1994.
  7. Patterson C, Chambers LW. Preventive health care. Lancet. 1995; 345: 1611-15.
  8. שינויים בשיגרת החיסונים 2003 - הוראות משת הבריאות שירותי בריאות הציבור המח׳ לאפידמיולוגיה, ירושלים 2003.
  9. הנחיות משרד הבריאות בנושא מעקב גדילה והתפתחות ילדים עד גיל 5. שירותי בריאות הציבור משרד הבריאות 1995 + עדכונים.
  10. המלצות הועדה המייעצת לארגון רופאי הילדים ספט' 1992.
  11. Valman HB. A B C of One to Seven. Published by the BMJ publishing Group, 3rd edition 1993.
  12. Fixler DE. and Pernoch LW. Validity of mass blood pressure screening in children. Pediatrics 1983; 72: 459-463.
  13. Palti H. Blood Pressure assessment in children. Isr. J Med Sci 1987; 23: 785-787.
  14. Zadik M, Sthoper D and Blachar Y. Blood Pressure determinations in Israeli school children aged 5 to 14 years. Isr. J Med Sci 1987; 23: 798-802.
  15. Report of the Second Task Force on Blood Pressure Control in Children--1987. Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland. Pediatrics 1987; 79: 1-25.
  16. Baron AE, Freyer B and Fixler DE. Longitudinal blood pressure in blacks, whites and Mexican Americans during adolescence and early adulthood. Am J Epdemiol 1986; 123: 809-817.
  17. הנחיות משרד הבריאות בנושא מעקב נשים בהריון, שירותי בריאות הציבור 1995 + עדכונים.
  18. Ewigman B G, Grane J P, frigoletto FD, Lefevre ML et al. Efect of prenatal ultrasaund screening on perinatal outcome. RADIVS Group. N Engl J Med 1993; 329 (12): 821-7.
  19. Berkowitz R L. Should every pregnant woman undrgo ultrasongraphy? N Engl J Med 1993; 329: 874-875.
  20. Bernaschek G, Stuempflen L. Deutinger J. The value of sonographic diagnosis of fetal malformation: different results between indication based investigations. Prenat Diagn 1994; 14(9): 807-812.
  21. Bragonier JR, Bemis Heys RL. Cost effectiveness in the provision of primary health care services for women. Prim Care Update Ob/Gyn: 1994; 11(6): 245-248.
  22. The Fifth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153: 154-83.
  23. Pyorala K, De Backer G, Graham P, Poole-Wilson P, Wood D. On behalf of the European Task force. Prevention of coronary heart disease in clinical Practice. European Heart Journal. 1994; 15: 1300-1331.
  24. Carruthers SG et al. Report of the Canadian Hypertension Society Consensus Conference. Can Med Assoc J 1993; 149 (3): 289-291/149 (4): 409418; 149 (5): 575-584; 149 (6): 815-26.
  25. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
  26. Expert Panel on Detection, and Treatment of high Blood Cholesterol in Adults. Summary of the second report of the National Cholestrol Educatin Program (NCEP) Expert Panel. JAMA 1993; 269: 3015-23.
  27. Krumholz HM et al. Lack of association between cholesterol and coronary Heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA 1994; 272 (17) 1335-1341.
  28. Willett WC. Diet and health, What should we eat. Science 1994; 264: 532-537.
  29. NIH Consensus Development Panel on optimal calcium intake. JAMA 1994; 272 (24): 1942-1948.
  30. Rich-Edwards JW, Manson JE, Hennekens CH et al. The primary prevention of coronary heart disease in women. N Eng J Med 1995; 332: 1758-1766.
  31. Austoker J. Cancer prevention in primary care — current trends and some prospects for the future -1. BMJ 1994; 309: 449452.
  32. American Cancer Society. Summary of current guidelines for the cancer-related checkups recommentdation. New York, American cancer Society, 1988.
  33. Treizenberg DJ, Smith AM, Holmes TM. Cancer screening and detection in Family practice, a MIRNET Study. J Fam Pract 1995; 40: 27-33.
  34. Austoker J. Screening and self-examination for breast cancer. BMJ 1994; 309: 168-174.
  35. Jatoi I, Baum M. American and European recommendations for screening mammography in younger Women: a cultural divide. BMJ 1993; 307: 1481-83.
  36. Mcpherson K, Steel CM, Dixon JM, Breast cancer — epidemiology, risk factors, and genetic. BMJ 1994; 309: 1003-1006.
  37. Shapiro s, Venet N, Strax A et al. Ten to fourteen years effects of screening on breast. JNC 1 1982; 69: 349-355.
  38. Wright C J & Mueller C B. Screening mammography and public health policy: the need for prespective. Lancet 1995; 346: 29-32.
  39. Austoker J. Screening for colorectal cancer. BMJ 1994; 309: 382-386.
  40. Winawer SJ. et al. WHO guidelines for the prevention of colorectal cancer: update based on new data. WHO Collaborating Center for prevention of Cancer, 1994.
  41. Mandel JS et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993; 328: 1365-1371.
  42. Allison JE. Tekawa IS, Ranosom L J et al. A Comparison of fecal occult blood tests for colorectal cancer screening. N Eng J Med 1996; 334: 155-159.
  43. Austoker J. Melanoma: Prevention and early diagnosis. BMJ 1994; 308: 1682-1686.
  44. Menczer J. Case against cytological mass screening for cervical cancer in Israel. Harefuah 1992; 120: 802-804.
  45. Austoker J, Sanders D, Fowler G. Smoking and Cancer: Smoking cessation. BMJ 1994; 308: 1478-82.
  46. Blum A, Solberg E. The role of the family physician in ending the Tabacco pandemic. J Fam Pract 1992; 34 (6): 697-699.
  47. Kottke TE et al. A controlled trial to Integrate smoking cessation advice into primary care practice: Doctors helping smokers, Round III. J Fam Pract 1992; 34 (6): 701-708.
  48. Poshuma FM, Westendorp GJ, Vandenbroucke JP, Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? BMJ 1994; 308: 1260-1270.
  49. American College of Physicians guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med 1992; 117: 1038-1041.
  50. Belchetz P. Hormonal treatment of postmenopausal women. N Eng J Med 1994; 330: 1062-64.
  51. Grady D et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1038-1041.
  52. Riggs BA & Melton L J. The prevention and treatment of osteoporosis. N Engl J Med 1992; 327 (9): 620-627.
  53. Colditz G A, Hankinson S E, Hunter D J et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Eng J Med 1995; 332: 1589-93.
  54. יתרונות וחסרונות הטיפול ההורמונלי התחליפי - עידכון. תרפיה שימושית בעריכת פהפ׳ רוזנפלד, ד"ר קיצס-כהן וד"ר גולדשמיד ־ אוקי 1994.
  55. Mead M. The over 75 Screening Card. Update 1991, May 987-994.
  56. When to use the new pneumococcal vaccine. Drugs Therap bull 1990 Apr 17: 28 (8): 31-32.
  57. Klinkman M S, Zazove P, Mehr DR & Ruffin MT. A Critierion-based review of priventive Health care in the elderly — Part 1. J Fam Pract 1992; 34: 205-22.
  58. Zazove P et al. Part 2 — A geriatric health maintenance program. J Fam pract 1992; 34: 320-347.
  59. Hepatitis B Virus. Recommendation of the Immunization Practices Advisory Committee (ACIP). MMWR 1991; 40: 1-25.
  60. Expanded programme of Immunization Programme Report for the year 1992. World Health Organization, January 1993.
  61. Hollinger FB. Factors influencing the immune response to Hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendatgions. Amer J Med 1989; 87 (suppl 3A): 365405.
  62. Hali AJ. Hepatitis B vaccination: protection for how long and against what? BMJ 1993; 307: 276-7.
  63. Barshani S, Avitzur M, Tur-Kaspa R. Antibodies to hepatitis C in Israeli blood donors: age, sex and ethnic differences from HBsAg positive carriers, first Joint spanish-Israeli Meeting on Liver and Biliary Disease, jerusalem 1992.
  64. Green MS, Block C, Slater PE. Rise in the incidence of viral hepatitis in Israel despite improved socioeconomic conditions. Reviews of Infectious Disease 1989; 11: 464-469.
  65. Bogomolski; Yahalom V, Granot N, Linder R, Korman S, Manny R, tur-Kaspa R, Shouval D. Prevalence of HBsAg carriers in native and immigrant pregnant female in Israel and passive/active vaccination against HBV of newborns at risk. J of Medical Virology 1991; 34: 217-222.
  66. Kramer BS, Brown ML, Prorok PC, Polosky AL, Gohagan JK. Prostate cancer screening what we know and what we need to know, ann Intern Med 1993; 119(9): 914-923.
  67. Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen year survival in prostate cancer a prospective, Population based study in sweden. JAMA 1997; 277(6): 467-71.
  68. Walsh PC, Brooks JD. The Swedish Prostate cancer paradox. JAMA 1997; 277(6) 497-498.
  69. Screening Mammography in women younger than 50 years of Age. Ann of Intern Med 1995; 122: 550-52.
  70. Nystrom L, Rutqvist LE, Wall S et al. Breast cancer screening with mammography over view of Swedish randomised trials. The Lancet 1993; 334(8851): 973-978.
  71. Lynge E. Definition and Ongoing Programs. Nationl Board of Health screening, Copenhagen 1992.
  72. The Breast screening brawl. Science; 1997; 275: 1056-1059.
  73. Adami HO. Prostate Cancer Screening — overview Int J Cancer: Supple 9. 1996; 3-12 Publication of the international union against cancer.
  74. Cochrane AL, Holland WW. Validation of screening procedures. Brit Med Bull. 1971; 27: 3-8.
  75. Screening. British Medical Bulletin edited by Peckham C, Dezatevx C. Published by the Royal Saciety of Medicine London 1998; 54(4) 767-85.
  76. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA.1998; 280: 605-613.
  77. Sidney, Petitti & Ruesenberry. Kaiser case control Study. Ann Int Med 1997; 127: 501-8.
  78. EPI Primary Results Paper. JAMA 1995; 273(3): 199-208.
  79. Delmas P.O. Bjarnason NH, Mitlak BH et al. Effects of Raloxifene on Bone Mineral Density. Serum cholesterol concentrations and uterine endometrium in postmenopausal women. NEJM 1997; 337: 1641-1647.
  80. Grodstein F. Stampfer MS, Colditz GM et al. Postmenopausal hormone therapy and mortality. NEJM 1997: 336: (25) 1769-1775.
  81. Whitehead M. Treatment for menopausal and post menopausal problems: present and future. Balliere's clinical obstetrics and gynaecology. 1996: 10(3): 515-529.
  82. Barrett Connor E. Hormone replacement therapy BMJ; 1998; 317: 457-61.
  83. Osteoporosis: Review of the evidence for prevention diagnosis and treatment and costeffective analysis. Executive Summary. Osteoporosis International: 1998; 8 Suppl 4:S3-6.
  84. Santoro N.F., Col N.F., Eckman M.H., Wong J.B., Pauker S.G., Cauley J.A., Zmuda J., Crawford S., Johannes C.B., Rossouw J.E., Merz C.N.B. Hormon Replaeement Therapy — Where are we going? JCEM 1999; 84; 6: 1798-1799.
  85. Osteoporosis — physicians guide to prevention and treatment of osteoporosis. Developed by the National Osteoporosis Foundation Washington 1997.
  86. Royal College of Physicians. Osteoporosis clinical guidelines for preventionnn and treatment, London: Royal College of Physicians, 1999.
  87. Battett-Connor E., Stuenkel C. Hormones and heart disease in women: Heart and estorgen/ progestin replacement study in perspective. JCEM 1999; 84; 6: 1848-9.
  88. Miller P.D., Zapalowski C, Kulak C.A.M., Bilezikian J.P. Bone densitometry: The best way to detect Osteoporosis and monitor therapy. JCEM 1999; 84; 6: 1867-8.
  89. Orwoll E.S., Nelson H.D. Does estrogen adequately protect postmenopausal women against osteoporosis: An inconoclastic perspective. JCEM 1999; 84; 6: 1872-3.
  90. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin interventions (PEPI) trial: The writingggg group for the PEPI. JAMA 1996; 276: 1389-1395.
  91. Michaelsson K, Baron JA, Farahmand, BY et al on behalf of the Swedish Hip Fracture Study Group. Hormone replacement therapy and risk of hip fracture: population based case control study. BMJ 1998; 316: 1858-1862.
  92. Santen J.R., Petroni G.R. Relative versus attributable risk of breast eancer from estorgen replacement therapay. JCEM 1999; 84; 6: 1875-6.
  93. Walsh B.W., The individualized approach to menopause management. JCEM 1999; 84; 6: 1900-1.
  94. Miettinen TA., Pyorala K., Olsson AG., et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Circulation. 1997; 96: 4211-4218.
  95. Lewis SJ., Sacks FM., Mitchell JS., et al. Effect of parvastatin on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) Trial. J Am College Cardiol. 1998; 32: 140-146.
  96. Downs JR., Clearfield M., Wies S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 1998; 279: 1615-622.
  97. Col NF., Eckman MH., Kara RH., et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA. 1997; 277: 1140-1147.
  98. Graday D., Rubin SM., Petitti DB., et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992; 117: 1016-1037.
  99. Nelson HD, Rizzo J, Harris E, Cauley J, Ensrud K, Bauer DC, Orwoll E; Study of Osteoporotic Fractures Research Group. Osteoporosis and fractures in postmenopausal women using estrogen. Arch Intern Med. 2002 Nov 11;162(20):2278-84.
  100. Bruce E., Dennis M.B., Bruce H.M., Ronald K.K., Thomas N., Harry K.G., Claus C, Pierr D.D., Jose RZ., Jacob S., Claus C.G., Dathrya K., Fredric J.C., Stephen E.,E., Louis V.A., Paul Lipa., Steven R.C. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. 1998, JAMA. 282; 637-645.
  101. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Eng J Med 1997; 337(4): 670-676.
  102. Storm T., Thamsborg G., Genant HK., Sorenson OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis N Eng J Med 1990; 333: 1437-1443.
  103. Van-Staa TP., Abenhaim L., Cooper C. Use of cyclical etidronate and prevention of non vertebral fractures. Br J Rheumatol 1998; 3777: 87-94.
  104. Liberman UA., Weiss SR., Broil J., Minne HW., Quan H., Bell NH., et al. Effect of oral Alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Eng J Med 1995; 333: 1437-1443.
  105. Fogelman I. Screening for osteoporosis. No point until we have resolved issues about long term treatment. BMJ 1999; 319: 1148-49.
  106. Lindsay R., Cosman F., Lobo RA., Walsh BW., et al. Addition of Alendronate to ongoing Hormone Replacement Therapy in the treatment of osteoporosis: A randomized controlled clinical trial. J Clin Endocrin Metab 1999; 84: 3076-81.
  107. המלצות הוועדה המדעית לחיסון ננגד דלקת נב1 נגיפית מסוג A, מתוך הנחיות קליניות - קווים מנחים, המלצות וניירות עמדה ברפואת המשפחה דו"ח הוועדה המקצועית מטעם האיגוד הישראלי לרפואת משפחה, ההסתדרות הרפואית בישראל, המועצה המדעית, האגף לאבטחת איכות והאגודה למלחמה בסרטן 1997 עמ׳ 76-71
  108. Furesz J, Scheifele D.W., Palkoyay L. Safety and effectiveness of the new inactivated hepatitis A virus vaccine. Can. Med. Assoc J. 1995; 152 (3): 343-8.
  109. Leentvaa K.A., Coutinho R.A., Brulein V. Safary A. Simultneous passive and active immunization against hepatitis A. Vaccine. 1992; 10 suppl 1: 13841.
  110. Innis BL, Snitbhan R, Kunasol P et al. Protection against hepatitis A by an inactivated vaccine. JAMA, 1994; 271: 1328-34.
  111. Horng Y.C., Chang M.H., Lee C.Y. et al Safety and immunogenicity of hepatitis A Vaccine in healthy children. Pediatr infect Dis J. 1993; 12: 359-62.
  112. Werzberger A., Mensch B., Kuter B. et al. A controlled trial of a formalin-inactivated hepatitis A Vaccine in healthy children. N. Engl J Med 1992; 327: 453-7.
  113. Bancrof W.H., Hepatitis A vaccine. N. Engl J. Ned. 1992; 327: 488-90.
  114. Tormans G., Van-Damme P., Van-Doorslaer E. Cost[effectiveness analysis of hepatitis A prevention in travellers. Vaccine. 1992 10 Suppl 1: 88-92.
  115. Van-Damme V., Cramm M., Van-der Auwera J., Meheus A. Hepatitis A Vaccintion in health care workers.
  116. Jilzey A.J., Palmer S.J., Barrow S. et al. Clinical trial with inactivated hepatitis A Vaccine and recommendations for its use. B.M. J. 1992; 304: 1272-76.
  117. Tilzey A.J., Banatvala J.E., Hepatitis A — changing prevalence and possible vaccines. B.M.J. 1991; 302: 1552-3.
  118. Prevention of Hepatitis A through active or passive immunization. Recommendations of the advisory commitee on immunization practices. U.S. Department of Health and Human Services. Center for Disease control and prevention 1995.
  119. Behrens R.H., Roberts J.A. Is travel prophylaxis worth while? Economic appraisal of profilactic measures against malaria, hepatitis A, and typhoid in travellers. B.M.J. 309: 918-22.
  120. Green M.S., Cohen D., Lerman Y., Sjogren M. et al. A trial of reactogenicity and immunogenicity of an inactivated heptitis A Vaccine, ISRAEL J. Med.Sci 1994; 30:485-88.
  121. Karetnyi Y. V., Mendelson E., Shlyakhov E, et al. Prevalence of antibodies against Hepatitis A virus ammong new immigrants in ISRAEL. J. Med. Virol 1995; 46: 61-65.
  122. Hepatitis A in ISRAEL — 1993. Monthly Epidemiological Record. Ministry of health, Department of Epidemiology ISRAEL. 1993.
  123. Bader T.F., Hepatitis A Vaccine. Am J. Gastroentero. 1996; 91(2): 217-22.
  124. Modan B., Shpilberg O., Sikuler E. et al. The need for liver transplantation: a nationwide estimate based on consesus review. Lancet. 1995: 346: 660-62.
  125. Ackerman Z., Ablin J, Shouval D. Active immunization against hepatitis A is now wannanted is G6PD deficient subjects. Am. J. Gastroenterol. 1996; 143.
  126. Krause D.S. Hepatitis A Vaxccines-letter to the editor. JAMA 1996; 276: 449450.
  127. Margolis H.S. Personal communication 1996.
  128. Adler R., Shouval D., Hepatitis A Prophylaxis. Vaccine or Immunoglobulin. Clin immunother 1996; 6(4): 261-272.
  129. Special report: Clinical preventive services: what's really worth doing for children from Contemporary Pediatrics. 1996; 13(3): 106-113.
  130. Bower C, Stanlly FJ. Issues in the prevention of spina bifida. J Royal society of Med. 1996; 89: 436-442.
  131. Laurence KM., James N., Miller MH., Tennant GB., Campbell H. Double blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural — tube defects. BMJ. 1981; 282: 1509-11.
  132. Bower C, Stanley FJ. Dietary Folate as a risk factor for neural tube defects: evidence from case — Control Study in Western — Australia. Med J of Australia. 1989; 150: 613-619.
  133. Milunsky A., Jick H., Jick S. et al. Multivitamin/Folic acid supplementation in early pregnancy reduces the prevalence of Neural Tube defects. JAMA 1989; 262(20): 2847-52.
  134. Swain RA., ST. Clair L. The role of Folic acid in deficiency States and prevention of disease J Fam Pract 1997; 44: 138-144.
  135. Law MR. Hackshaw AK. A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. BMJ 1997; 315: 841-46.
  136. Philips A, Wannamethee SG, Walker M, et al. Life expectancy in men who have never smoked and those who have smoked continuously: 15 years follow-up of large cohort of middle aged British men BMJ 1996; 313: 907-8.
  137. סלע ב. המערכה מד עישון: האם אנו מתקרבים לרגע האמתל הרפואה 1996; כרך 131 עמ׳ 530-524.
  138. Hastings G, Macfadyen L, Stead M. Tabacco marketing: shacking the pied piper. BMJ 1997; 315: 43940.
  139. Davis RM. Passive smoking: history repeats itself. BMJ 1997; 315: 961-2.
  140. Hackshow AK, Law MR, Wald NJ. The accumulated evidence on lung cancer and environmental tabacco smoke. BMJ 1997; 315: 980-88.
  141. Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE. The primary prevention of coronary heart disease in women. N Enql J Med 1995; 332: 1758-66.
  142. Powell KE. Physical activity and health. BMJ 1996; 313: 126-7.
  143. Jones TF, Eaton CB. Exercise Prescription. Am Fam Physician 1995; 52: 543-553.
  144. Doll R, Peto R, Hall E, Weatley K, Gray R. Alcohol and Coronary heart disease reduction among British Doctors: Confounding and causality Eur. Heart J 1997; 18(1): 23-5.
  145. Shaper AG, Wannamethee G, Walker M. Alcohol and Coronary heart disease: a perspective from the British Regional Heart study. Int J Epidemiol 1994; 23(3): 482-94.
  146. Mcdonald P, Friedman EHI, Banks A, et al. Pneumococcal vaccine canpaign based in general practice BMJ 1997; 314: 1094-8.
  147. קופ"ח כללית ההנהלה המרכזית חוזר מרוכז 17/97 מיום 21.7.97 עמ׳ 10.
  148. Dowse GK, Gareeboo H, Alberti KG, et al. Changes in population cholesterol concerntrations and other cardiovascular risk factor levels after five years of the non-communicable disease intervention program in Mauritius. BMJ 1995; 311: 1255-59.
  149. יאיר יודפת. היפרליפידמיה - מה חדש ואיך נטפל. כתב העת הישראלי לרפואת משפחה Israel Journal of Family Practice כרך 8 11-4 ‏ 1998,48
  150. יאיר יודפת. מניעה בזיקנה - סקירה ראשית. כתב העת הישראלי לרפואת המשפחה Israel Journal of Family Practice פבר׳ 1996 כרך 26 עמי 10-4
  151. Patterson CH, Feightner J. Promoting the health of senior citizens. Can Med Assoc J 1997; 157(8): 1107-13.
  152. Organizing committee of the Canadian consensus conference on the assessment of dementia. Can Med Assoc. J 1991; 144(7): 851-3.
  153. Goldberg TH, Chavin SI. Preventive medicine and screening in the older adults. JAGS. 1997; 45(3): 344-54.
  154. Feightner JW, Gass DA, Bass MJ. An approach to assessing dementia. Can Fam Physician. 1992; 38: 2347-53.
  155. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with Isolated systolic hypertention. JAMA 1991; 265: 3255-65.
  156. Joint National Committee on Detection, evaluation and treatment of high blood pressure. The sixth report of the National Committee on Detedion evaluation and treatment of high blood pressure (JNC VI). Arch Intern Med 24 Nov. 1997.
  157. Lever AF, Ramsey LE. Treatment of hypertension in the elderly. J Hypertens 1995; 13: 571-9.
  158. Towler B, Irwig L, Glasziou P, et al. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test — Hemoccult. BMJ 1998; 317: 559-65.
  159. Lahad A, Malter AD, Berg A, Deyo RA. The effectiveness of four interventions for the prevention of low back pain. JAMA 1994; 272: 1286-91.
  160. Daltroy LH; Iversen MD; Larson MG; et al. A controlled trial of an educational program to prevent low back injuries. N Engl J Med, 1997; 337: 322-8.
  161. Reddell CR, Congleton JJ, Huchingson RD, Montgomery JF. An evaluation of a weightlifting belt and back injury prevention training class for airline baggage handlers. Applied Ergonomics. 1992; 23: 319-329
  162. Cox JM, Trier KK. Exercise and smoking habits in patients with and without low back and leg pain. J Manipulative Physiol Ther. 1987; 10: 239-45.
  163. Battie MC, Videman T, Gill K, et al. Smoking and lumbar intervertebral disk degeneration: An MRI study of identical twins. Spine. 1991; 16: 1015-21.
  164. Holm S, Nachemson A. Nutrition of the intervertebral disc: acute effects of cigarette smoking. An experimental animal study. Ups J Med Sci. 1988; 93: 91-9.
  165. Gore DG, Passehl R, Sepic S, et al. Scoliosis screening: results of community project. Pediatrics 1981; 67: 196-200.
  166. Morais T, Bernier M, Turcotte F. Age and sex specific prevalence of scoliosis and the value of school programs. Am J Public Health 1985; 75: 1377-80.
  167. U.S. Preventive Services Task Force. Screening for adolescent idiopathic scoliosis: review article. JAMA 1993; 269: 2667-2672.
  168. Willers U, Normelli H, Aaro S, et al. Long-term results of Boston brace treatment on vertebral rotation in idiopathic scoliosis. Spine 1993; 18: 432-35.
  169. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151: 1283-90.
  170. Breslow N, Chan CW, Dhom G, et al. Latent carcinoma of prostate at autopsy in seven areas. Int J Cancer. 1977; 20: 680-88.
  171. Friedman GD, Hiatt RA, Quesenberry CP, et al. Case-control study of screening for prostate cancer by digital rectal examination. Lancet 1991; 337: 1526-29.
  172. Gerber GS, Tompson IM, Thistad, et al. Disease-specific survival following routine prostate cancer screening by digital rectal examination. JAMA; 1993; 269: 61-64.
  173. Mold JW, Holtgrave DR, Bisonni RS, et al. The evaluation and treatment of men with asymptomatic prostate nodules in primary care: a decision analysis. J Fam Pract. 1992; 34: 561-68.
  174. Krahn MD, Mahoney JE, Eckman MH, et al. Screening for prostate cancer: a decision analysis view. JAMA 1994; 272: 773-80.
  175. Cantor SB, Spann SJ, Volk RJ, et al. Prostate cancer screening: a decision analysis. J Fam Pract 1995; 41: 33-41.
  176. Beatt GZ. The value of lung cancer detection by six-monthly chest radiographs. Thorax 1968; 23: 414-20.
  177. Weiss W. Survivorship among men with bronchogenic carcinoma: three studies in populations screened every six months. Arch Environ Health 1971; 22: 168-73.
  178. Ebeling K, Nischan P. screening for lung cancer: results from a case-control study. Int J Cancer 1987; 40: 141-44.
  179. Kubik A, Parkin DM, Khlat M, et al. Lack of benefit from smi-annual screening for cancer of the lung: follow-up report of a randomized controlled trail on a population of high-risk males in Czechoslovakia. Int J Cancer 1990; 45: 26-33.
  180. Andolf E, Svalenius E, Astedt B. Ultrasonography for early detection of ovarian carcinoma. Br J Obstet Gynecol 1986; 93: 1286-89.
  181. Jacobs I. Screening for early ovarian cancer. Lancet 1988; 2: 171-172.
  182. Jacobs I, Stabile I, Bridges J, et al. Multimodal approach to screening for ovarian cancer. Lancet 1988; 1: 268-271.
  183. Levy-Lahad E, Catane R, Eisenberg S, et al. Founder BRCAI and BRCA2 mutations in Ashkenazi Jews in Israel: Frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. In press, Am J Human Genetics 1997; 60: 1059-67.
  184. Kemp HG, Kronmal RA, Vietstra RE, Frye FL. Seven year survival of patients with normal or near normal coronary arteriograms: a CASS registry study. J Am Coll Cardiol 1986; 7: 479-83.
  185. Rose 6, Baxter PJ, Reid DD, MaCartney P. Prevalence and prognosis of electrocardio-graphic findings in middle-age men. Br Heart J 1978; 40: 636-43.
  186. Multiple Risk Factor Intervention Trail Reserch Group. Baseline electrocardiographic abnormalitis, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trail. Am J Cardiol 1985; 55: 1-15.
  187. Knutsen R, Knutsen SF, Curb JD, et al. The predictive value of resting electrocardiograms for 12 year incidence of coronary heart disease in Honolulu Heart Program. J Clin Epidemiol 1988; 41: 293-302.
  188. Weiner DA, Backer L, Bonow R. The diagnostic and prognostic significance of an asymptomatic positive exercise test Circulation 1987; 75: II-20-1.
  189. Josephson RA, shefrin E, Lakatta EG, et al. Can serial exercise testing improve prediction of coronary events in asymptomatic individual? Circulation 1990; 81: 20-4.
  190. McHenry PL, ODonnell J, Morris SN, Jordan JJ. The abnormal exercise electrocardiogram in apparently healthy man: a predictor of angina pectoris as an intial coronary event during long-term follow-up. Circulation 1984; 70: 547-51.
  191. Fleg JL, Gerstenblith G, Zonderman AB, et al. Prevalence and prognostic significance of exercise-induced silent myocardial ischemia detected by thallium scintigraphy and electrocardiography in asymptomatic volunteers. Circulation 1990; 81: 428-36.
  192. Epstein SE, Quyumi A, Bonow RO. Sudden cardiac death without warning: possible mechanisims and implications for screening asymptomatic populations. N Engl J Med 1989; 321: 320-23.
  193. Heering SL, Beller U, Baras M, et al. A cohort analysis of cervical cancer in Israeli jewish women. Gynecol Oncol, 1990; 39: 24448.
  194. Okamura K, Ueda K, Sone H, et al. A sensitive thyroid stimulation hormone assay for screening of thyroid function disorder in elderly Japanese. J Am Geriatr Soc 1989; 37: 317-322.
  195. Helfand M, Crapo LM. Screening for thyroid disease. Ann Inter Med 1990; 112: 840-49.
  196. De 10s Santos ET, Starich GH, Mazzaferri EL. Sensitivity, specifisity, and cost-efFectiveness of the sensitive thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients. Arch Intern Med 1989; 149: 526-32.
  197. Franklyn JA. The management of hyperthyroidism!. N Engl J Med. 1994; 330: 1731-38.
  198. Fletcher S. Breast cancer Screening in women aged under 50. BMJ 1997; 314: 764-5.
  199. Tomati L, Aitio A, et al. Cancer: Causes, Occurrence and Control. International Agency for Research on Cancer Scientific Publications. No. 100. WHO, IARC, 1990; Lyon, France.
  200. Greenwald P, Kramer BS, Weed DL. Cancer Prevention and Control. Marcel Dekker Inc. 1995; New York, USA.
  201. Stoll B, Love SM. Reducing Breast Cancer Risk in Women. Kluwer Academic Publications 1995; Dordrecht, The Netherlands.
  202. Parkin DM, Muir CS. Cancer Incidence in Five Continents. International Agency for Research on Cancer Scientific Publications, 1992; Vol. VI. No. 120, WHO, IARC, Lyon, France.
  203. Kelsy JL, Hildreth NG. Breast and Gynecologic Cancer Epidemiology, CRC Press Inc. 1983; Boca Raton, Florida, U.S.A.
  204. Kelsy JL, Bernstein L. Epidemiology and Prevention of Breast Cancer. Annu Rev Public Health 1996;17:47-67.
  205. Rimm EB, Williams P, Fosher K et al Moderate Alcohol intake and lower risk of coronary heart disease: Meta-analysis of effects on lipids and haemostatic factors. BMJ 1999; 319: 1523-8.